Praxis Precision Medicines, Inc.(PRAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PRAX Praxis Precision Medicines, Inc.

Not Yet Opened 04-15 16:00:00 EDT

339.93

-3.67

-1.07%

盘后339.93

+0.000.00%

17:28 EDT

High350.00	Low330.00	Vol514.41K
Open348.04	D1 Closing343.60	Amplitude5.82%
Mkt Cap9.47B	Tradable Cap8.76B	Total Shares27.85M
T/O174.65M	T/O Rate2.00%	Tradable Shares25.78M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PRAX","market":"US","secType":"STK","nameCN":"Praxis Precision Medicines, Inc.","latestPrice":339.93,"timestamp":1776283200000,"preClose":343.6,"halted":0,"volume":514410,"hourTrading":{"tag":"盘后","latestPrice":339.93,"preClose":339.93,"latestTime":"17:28 EDT","volume":24735,"amount":8408171.59,"timestamp":1776288523765,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.010681024447031477,"floatShares":25778700,"shares":27850833,"eps":-13.475777,"marketStatus":"Not Yet Opened","change":-3.67,"latestTime":"04-15 16:00:00 EDT","open":348.04,"high":349.9999,"low":330,"amount":174653527.45229998,"amplitude":0.058207,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-13.475777,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1776326400000},"marketStatusCode":0,"adr":0,"listingDate":1602820800000,"exchange":"NASDAQ","adjPreClose":343.6,"preHourTrading":{"tag":"盘前","latestPrice":350,"preClose":343.6,"latestTime":"09:26 EDT","volume":50,"amount":17514.97,"timestamp":1776259586890,"change":6.4,"changeRate":0.018626,"amplitude":0.014523},"postHourTrading":{"tag":"盘后","latestPrice":339.93,"preClose":339.93,"latestTime":"17:28 EDT","volume":24735,"amount":8408171.59,"timestamp":1776288523765,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.391167,"impliedVol":0.8681,"impliedVolPercentile":0.51},"requestUrl":"/m/hq/s/PRAX/tweets","defaultTab":"tweets","newsList":[{"id":"2627289154","title":"Deutsche Bank Adjusts Praxis Precision Medicines Price Target to $437 From $412, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2627289154","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627289154?lang=en_us&edition=fundamental","pubTime":"2026-04-15 19:39","pubTimestamp":1776253145,"startTime":"0","endTime":"0","summary":"Deutsche Bank Adjusts Praxis Precision Medicines Price Target to $437 From $412, Maintains Buy Rating","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DB","PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627422744","title":"Praxis Precision NDA for Ulixacaltamide in Essential Tremor","url":"https://stock-news.laohu8.com/highlight/detail?id=2627422744","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627422744?lang=en_us&edition=fundamental","pubTime":"2026-04-15 05:30","pubTimestamp":1776202211,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines ( ($PRAX) ) has shared an update. On April 14, 2026, Praxis Precision Medicines, Inc. announced that the U.S. Food and D...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/praxis-precision-nda-for-ulixacaltamide-in-essential-tremor?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/praxis-precision-nda-for-ulixacaltamide-in-essential-tremor?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0109394709.USD","IE00B4R5TH58.HKD","BK4139","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","IE0002141913.USD","LU0320765992.SGD","PRAX","IE00BFTCPJ56.SGD","LU0889565916.HKD","IE00B2B36J28.USD","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627440813","title":"Praxis Precision Med Price Target Maintained With a $510.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2627440813","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627440813?lang=en_us&edition=fundamental","pubTime":"2026-04-14 23:08","pubTimestamp":1776179280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PRAX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 14, 2026 11:08 ET (15:08 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Praxis Precision Med Price Target Maintained With a $510.00/Share by Needham","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","PRAX","IE00B2B36J28.USD","LU0320765992.SGD","IE00BFTCPJ56.SGD","LU0889565916.HKD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","IE0002141913.USD","LU0109394709.USD","BK4139","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627442700","title":"Praxis Precision Medicines Shares Rise After FDA Accepts New Drug Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2627442700","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627442700?lang=en_us&edition=fundamental","pubTime":"2026-04-14 22:32","pubTimestamp":1776177120,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines shares rose after the Food and Drug Administration accepted its new drug application for ulixacaltamide HCl in the treatment of essential tremor in adults.Shares of the biopharmaceutical company rose 7.9% on Tuesday to $342.09. The company's shares are up 16% year to date.The drug went through a Phase 3 program with two studies of adults and received breakthrough therapy designation from the FDA in 2025. The FDA has set a target action date of Jan. 29, 2027, the company said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","LU0889565916.HKD","IE0002141913.USD","BK4139","BK4585","LU0109394709.USD","IE00BFTCPJ56.SGD","IE0009355771.USD","PRAX","LABU","LU0320765992.SGD","BK4588","IE00BJT1NW94.SGD","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627443355","title":"Praxis says FDA accepts NDA review for essential tremor drug ulixacaltamide","url":"https://stock-news.laohu8.com/highlight/detail?id=2627443355","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627443355?lang=en_us&edition=fundamental","pubTime":"2026-04-14 19:32","pubTimestamp":1776166330,"startTime":"0","endTime":"0","summary":"FDA accepted Praxis Precision Medicines NDA for ulixacaltamide HCl to treat essential tremor in adults.PDUFA target action date set for Jan. 29, 2027.Agency does not expect to convene an advisory committee meeting.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nNDL2bT00H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00BJT1NW94.SGD","BK4139","LU2210150020.SGD","SG9999014021.USD","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","SG9999014005.SGD","LU0314104364.USD","SG9999014039.USD","LU0109394709.USD","IE0002141913.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","LU0889565916.HKD","SG9999014013.SGD","LU0320765992.SGD","NDAQ","IE00B3QW5Z07.USD","IE00B4R5TH58.HKD","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","BK4588","LU2210149790.SGD","PRAX","IE00BFTCPJ56.SGD","LU2095319765.USD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","IE0009355771.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627448040","title":"Praxis Precision Medicines Inc - FDA Sets Pdufa Target Action Date of January 29, 2027 for Ulixacaltamide","url":"https://stock-news.laohu8.com/highlight/detail?id=2627448040","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627448040?lang=en_us&edition=fundamental","pubTime":"2026-04-14 19:30","pubTimestamp":1776166200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nTUA1P7GWL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","IE0002141913.USD","IE0009355771.USD","IE00B4R5TH58.HKD","LU0889565916.HKD","PRAX","LU0320765992.SGD","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627011448","title":"Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide Hcl in Patients With Essential Tremor","url":"https://stock-news.laohu8.com/highlight/detail?id=2627011448","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627011448?lang=en_us&edition=fundamental","pubTime":"2026-04-14 19:30","pubTimestamp":1776166200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260414:nTUA1P7GWL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE0009355771.USD","IE00BJJMRZ35.SGD","LU0320765992.SGD","BK4139","LU0889565916.HKD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","LU0109394709.USD","PRAX","IE00BFTCPJ56.SGD","IE0002141913.USD","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627998450","title":"Praxis Precision Medicines: Advancing CNS Pipeline and Near-Term Data Catalysts Support Buy Rating Despite Cash Burn","url":"https://stock-news.laohu8.com/highlight/detail?id=2627998450","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627998450?lang=en_us&edition=fundamental","pubTime":"2026-04-14 01:55","pubTimestamp":1776102925,"startTime":"0","endTime":"0","summary":"Francois Brisebois, an analyst from LifeSci Capital, maintained the Buy rating on Praxis Precision Medicines. The associated price target remains t...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/praxis-precision-medicines-advancing-cns-pipeline-and-near-term-data-catalysts-support-buy-rating-despite-cash-burn-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/praxis-precision-medicines-advancing-cns-pipeline-and-near-term-data-catalysts-support-buy-rating-despite-cash-burn-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRAX","CNS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627769430","title":"Praxis reports positive Phase 3 Essential3 trial results for ulixacaltamide in essential tremor","url":"https://stock-news.laohu8.com/highlight/detail?id=2627769430","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627769430?lang=en_us&edition=fundamental","pubTime":"2026-04-13 20:03","pubTimestamp":1776081836,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines outlined expanded analyses from Phase 3 Essential3 program of ulixacaltamide for essential tremor, with results set for presentation at AAN 2026 in Chicago on April 18-22.Essential3 was described as first positive Phase 3 program in essential tremor, supporting FDA Breakthrough Therapy Designation for ulixacaltamide.Plenary presentation on April 21 will focus on durability of response from Essential3 Study 2, a randomized withdrawal trial.Poster presentations on April 20 will cover topline efficacy and safety outcomes from Essential3 Study 1, alongside a combined program analysis.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nNDL4k98Gr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B64PRP62.GBP","LU2095319765.USD","NDAQ","SG9999014005.SGD","LU0109394709.USD","LU0889565916.HKD","BK4588","SG9999014013.SGD","LU0314104364.USD","BK4112","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","SG9999014039.USD","BK4585","BK4139","IE00B3QW5Z07.USD","IE00BN0W2T93.GBP","LU2210149790.SGD","IE00BJJMRZ35.SGD","PRAX","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","LU0320765992.SGD","IE0002141913.USD","IE0009355771.USD","LU2210150020.SGD","IE00BKPKM429.USD","IE00B4R5TH58.HKD","SG9999014021.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626194925","title":"Raymond James Initiates Praxis Precision Medicines at Strong Buy With $815 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2626194925","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626194925?lang=en_us&edition=fundamental","pubTime":"2026-04-10 19:16","pubTimestamp":1775819804,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines (PRAX) has an average rating of buy and mean price target of $629.24, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research fr","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PRAX","RJF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626123196","title":"Praxis Precision initiated with a Strong Buy at Raymond James","url":"https://stock-news.laohu8.com/highlight/detail?id=2626123196","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626123196?lang=en_us&edition=fundamental","pubTime":"2026-04-10 17:40","pubTimestamp":1775814021,"startTime":"0","endTime":"0","summary":"Raymond James last night initiated coverage of Praxis Precision (PRAX) with a Strong Buy rating and $815 price target The firm says the bear thesis...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/praxis-precision-initiated-with-a-strong-buy-at-raymond-james-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/praxis-precision-initiated-with-a-strong-buy-at-raymond-james-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B64PRP62.GBP","LU0109394709.USD","LU0889565916.HKD","BK4588","RJF","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","IE00BJT1NW94.SGD","LU0971096721.USD","BK4585","BK4139","IE00B3QW5Z07.USD","IE00BJJMRZ35.SGD","PRAX","IE00BGHQF748.EUR","BK4127","LU0320765992.SGD","IE0002141913.USD","IE0009355771.USD","LU2265009873.SGD","LU1363072403.SGD","LU1804176565.USD","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625843958","title":"Praxis: EMBRAVE Data Validate Elsunersen and De‑Risk Pipeline, Supporting Buy Rating on Favorable Risk‑Reward","url":"https://stock-news.laohu8.com/highlight/detail?id=2625843958","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625843958?lang=en_us&edition=fundamental","pubTime":"2026-04-07 20:15","pubTimestamp":1775564125,"startTime":"0","endTime":"0","summary":"Analyst Rudy Li of Wolfe Research maintained a Buy rating on Praxis Precision Medicines, retaining the price target of $500.00. Rudy Li has given h...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/praxis-embrave-data-validate-elsunersen-and-de‑risk-pipeline-supporting-buy-rating-on-favorable-risk‑reward-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/praxis-embrave-data-validate-elsunersen-and-de‑risk-pipeline-supporting-buy-rating-on-favorable-risk‑reward-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B2B36J28.USD","IE00BJT1NW94.SGD","IE0009355771.USD","LU0889565916.HKD","LU0109394709.USD","LU0320765992.SGD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","BK4139","IE00BFTCPJ56.SGD","IE0002141913.USD","PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625602856","title":"Praxis reports positive elsunersen trial in pediatric epilepsies","url":"https://stock-news.laohu8.com/highlight/detail?id=2625602856","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625602856?lang=en_us&edition=fundamental","pubTime":"2026-04-07 05:08","pubTimestamp":1775509713,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Praxis Precision Medicines ( ($PRAX) ). Praxis Precision Medicines reported positive topline results from its E...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/praxis-reports-positive-elsunersen-trial-in-pediatric-epilepsies?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/praxis-reports-positive-elsunersen-trial-in-pediatric-epilepsies?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","BK4139","IE0002141913.USD","LU0889565916.HKD","IE00B4R5TH58.HKD","LU0109394709.USD","IE0009355771.USD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","PRAX","LU0320765992.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625601553","title":"FDA accepts Praxis relutrigine NDA for priority review, sets Sept. 27, 2026 decision date","url":"https://stock-news.laohu8.com/highlight/detail?id=2625601553","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625601553?lang=en_us&edition=fundamental","pubTime":"2026-04-07 04:24","pubTimestamp":1775507078,"startTime":"0","endTime":"0","summary":"FDA accepted Praxis NDA for relutrigine to treat SCN2A, SCN8A developmental and epileptic encephalopathies under priority review.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Praxis Precision Medicines Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 06, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nNDL4R3BZG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","IE00B2B36J28.USD","LU0320765992.SGD","IE00BJT1NW94.SGD","LU0109394709.USD","IE00B4R5TH58.HKD","BK4139","PRAX","IE0002141913.USD","IE00BFTCPJ56.SGD","IE0009355771.USD","IE00BJJMRZ35.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625142603","title":"BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Norfolk Southern, Denali","url":"https://stock-news.laohu8.com/highlight/detail?id=2625142603","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625142603?lang=en_us&edition=fundamental","pubTime":"2026-04-07 01:51","pubTimestamp":1775497861,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Tesla, Norfolk Southern, DenaliWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nL6N40P09M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RKT","TSLZ","TSLT","FAF","PRAX","ONCY","VLO","ADM","CAR","CVNY","NVDA","NVDD","IBRX","IDYA","CVX","LGN","TSN","OXY","DVN","07766","ATMU","XOM","SLNO","NVD","WTBA","TSLY","KTOS","EXPE","NSC","AGPU","LYB","TLA","CVNA","DOW","TSLI","AMD","CVNX","AESI","TSLS","TSLW","TSLR","QCOM","AVGO","DIPS","PFSA","ELAB","BKNG","TSLA","DNLI","WLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625760813","title":"Praxis Precision Medicines: Advancing Late-Stage Neurology Pipeline Underpins Outperform Rating and $53 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2625760813","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625760813?lang=en_us&edition=fundamental","pubTime":"2026-04-07 00:55","pubTimestamp":1775494519,"startTime":"0","endTime":"0","summary":"Praxis Precision Medicines, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Francois Brisebois from LifeSci Ca...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/praxis-precision-medicines-advancing-late-stage-neurology-pipeline-underpins-outperform-rating-and-53-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/praxis-precision-medicines-advancing-late-stage-neurology-pipeline-underpins-outperform-rating-and-53-price-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SSI","PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625670770","title":"Praxis Precision Med Price Target Maintained With a $843.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2625670770","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625670770?lang=en_us&edition=fundamental","pubTime":"2026-04-07 00:24","pubTimestamp":1775492640,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PRAX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 06, 2026 12:24 ET (16:24 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","IE00BJT1NW94.SGD","IE0009355771.USD","LU0889565916.HKD","LU0109394709.USD","LU0320765992.SGD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","BK4139","IE00BFTCPJ56.SGD","IE0002141913.USD","PRAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625670663","title":"BUZZ-U.S. STOCKS ON THE MOVE-Tyson Foods, Atmus Filtration, Avis Budget","url":"https://stock-news.laohu8.com/highlight/detail?id=2625670663","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625670663?lang=en_us&edition=fundamental","pubTime":"2026-04-06 23:44","pubTimestamp":1775490252,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Tyson Foods, Atmus Filtration, Avis BudgetWorkspace search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nL6N40P0IG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMDD","PRAX","BKNG","NVDA","ELAB","DIPS","FAF","CVNA","ONCY","WTBA","DOW","AMDW","XOM","AGPU","ATMU","CAR","AMDL","CVX","IDYA","TSN","LGN","AMDY","EXPE","AMUU","AMDG","QCOM","SNVD.UK","IBRX","OXY","QCMD","AVGG","AESI","WLK","KTUP","LYB","AVGU","ANV","RKT","PFSA","QCMU","KTOS","AMDU","DVN","QCML","AMYY","SLNO","AMD","VLO","ADM","AVGO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625559674","title":"BUZZ-Praxis Precision Medicines rises as epilepsy drug cuts seizures in children","url":"https://stock-news.laohu8.com/highlight/detail?id=2625559674","media":"Reuters","labels":["shareholding","productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625559674?lang=en_us&edition=fundamental","pubTime":"2026-04-06 21:12","pubTimestamp":1775481161,"startTime":"0","endTime":"0","summary":"BUZZ-Praxis Precision Medicines rises as epilepsy drug cuts seizures in children** Shares of biotech firm Praxis Precision Medicines PRAX.O rise 4.7% to $325 premarket** Co says its experimental drug elsunersen cut seizures in a rare form of childhood epilepsy; SCN2A-DEE is a genetic brain disorder that begins early in life and causes frequent, hardtotreat seizures** Co says early-stage study in nine children showed a 77% cut in monthly seizures versus placebo** Says 71% of treated children saw seizures fall by more than half after six months, with benefits lasting up to a year** Adds children also showed gains in sleep, movement, muscle tone and attention; no serious safety issues seen** Says it is running a larger trial and will share more data at scientific meetings** As of last close, stock up ~5% YTD  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nL4N40P0NM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B4R5TH58.HKD","LU0109394709.USD","IE00BJJMRZ35.SGD","LU0320765992.SGD","LU0889565916.HKD","PRAX","BK4139","IE0009355771.USD","IE0002141913.USD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625227679","title":"BRIEF-Praxis Precision Medicines Announces Positive Results From The Embrave Part A Trial Of Elsunersen In Patients With Scn2a Early-Onset Developmental And Epileptic Encephalopathy","url":"https://stock-news.laohu8.com/highlight/detail?id=2625227679","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625227679?lang=en_us&edition=fundamental","pubTime":"2026-04-06 20:19","pubTimestamp":1775477996,"startTime":"0","endTime":"0","summary":"BRIEF-Praxis Precision Medicines Announces Positive Results From The Embrave Part A Trial Of Elsunersen In Patients With Scn2a Early-Onset Developmental And Epileptic EncephalopathyApril 6 (Reuters) -","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260406:nTUA7JM4VW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0002141913.USD","BK4139","LU0889565916.HKD","LU0320765992.SGD","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","LU0109394709.USD","IE00B4R5TH58.HKD","IE00BJT1NW94.SGD","IE0009355771.USD","PRAX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.praxismedicines.com","stockEarnings":[{"period":"1week","weight":0.0616},{"period":"1month","weight":0.1145},{"period":"3month","weight":0.1417},{"period":"6month","weight":0.7892},{"period":"1year","weight":10.457},{"period":"ytd","weight":0.1533}],"compareEarnings":[{"period":"1week","weight":0.0354},{"period":"1month","weight":0.0462},{"period":"3month","weight":0.0111},{"period":"6month","weight":0.0535},{"period":"1year","weight":0.3019},{"period":"ytd","weight":0.0264}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase IIb clinical trial for the treatment of essential tremor, as well as in Phase II clinical trial to treat Parkinson's disease; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. Praxis Precision Medicines, Inc. was incorporated in 2015 and is based in Boston, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.298328},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.166549},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.160217},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.006171},{"month":5,"riseRate":0.4,"avgChangeRate":-0.124101},{"month":6,"riseRate":0.4,"avgChangeRate":-0.094382},{"month":7,"riseRate":0.6,"avgChangeRate":0.167978},{"month":8,"riseRate":0.4,"avgChangeRate":0.080633},{"month":9,"riseRate":0.6,"avgChangeRate":0.013557},{"month":10,"riseRate":0.6,"avgChangeRate":0.512334},{"month":11,"riseRate":0.666667,"avgChangeRate":0.073478},{"month":12,"riseRate":0.833333,"avgChangeRate":0.206625}],"exchange":"NASDAQ","name":"Praxis Precision Medicines, Inc.","nameEN":"Praxis Precision Medicines, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.41.0","shortVersion":"4.41.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Praxis Precision Medicines, Inc.(PRAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Praxis Precision Medicines, Inc.(PRAX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Praxis Precision Medicines, Inc.,PRAX,Praxis Precision Medicines, Inc.股票,Praxis Precision Medicines, Inc.股票老虎,Praxis Precision Medicines, Inc.股票老虎国际,Praxis Precision Medicines, Inc.行情,Praxis Precision Medicines, Inc.股票行情,Praxis Precision Medicines, Inc.股价,Praxis Precision Medicines, Inc.股市,Praxis Precision Medicines, Inc.股票价格,Praxis Precision Medicines, Inc.股票交易,Praxis Precision Medicines, Inc.股票购买,Praxis Precision Medicines, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Praxis Precision Medicines, Inc.(PRAX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Praxis Precision Medicines, Inc.(PRAX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction